Tests MxA and CRP blood markers to guide antibiotic use in COPD flare-ups
Tests whether MxA and CRP blood tests guide antibiotic treatment in adults with COPD flare-ups.
Plain-language title generated from the registry record
Registry title: MxA and CRP-Guided Use of Antimicrobial Agents for AECOPD
Key facts
- Where
- Beijing, ChinaSee the site
Where in China
- China-Japan Friendship HospitalBeijing, ChinaNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Capital Medical University
- Trial code
- NCT06779344
- Record updated
- 16 January 2025
- Original description
This randomized controlled trial will investigate the clinical impact of Myxovirus Resistance A (MxA) and C-Reactive Protein (CRP)-guided antimicrobial treatment compared to usual care in outpatients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD).Read full original descriptionShow less
Myxovirus Resistance Protein a and C-Reactive Protein-Guided Antimicrobial Treatment in Outpatients with Acute Exacerbations of Chronic Obstructive Pulmonary Disease
This randomized controlled trial will investigate the clinical impact of Myxovirus Resistance A (MxA) and C-Reactive Protein (CRP)-guided antimicrobial treatment compared to usual care in outpatients with acute exacerbations of chronic obstructive pulmonary disease (AECOPD).
Inclusion: ≥40 years old；; Current or former smoker with a minimum smoking history of 10 pack years, clinical diagnosed with mild-to-severe COPD; Presenting with an acute exacerbation of COPD; The severity of AECOPD is mild to moderate.
Exclusion: Received interferon therapy within 30 days before screening; Had an active systemic inflammatory condition within 30 days prior to screening, such as cerebral infarction, myocardial infarction, or surgery; Received vaccine in the past 30 days; Had a concurrent infection at another site, such as urinary tract infections or sinusitis; Pre-treatment with corticosteroids (cumulative dose of methylprednisolone ≥ 80 mg or equivalent dose) for the present exacerbation; Active tuberculosis; Presenting with current respiratory failure; Required urgent hospitalization; Immunocompromised; Clinical suspicion of pneumonia or pulmonary edema; Coexisting bronchiectasis, cystic fibrosis, or asthma; Contraindications to antibiotics and/or antivirals; Known etiology of the present exacerbation.